- Home
- RARE vs SFBS Comparison
RARE vs SFBS Comparison
Compare RARE & SFBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- SFBS
- Stock Information
- Founded
- RARE 2010
- SFBS 2005
- Country
- RARE United States
- SFBS United States
- Employees
- RARE N/A
- SFBS N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- SFBS Major Banks
- Sector
- RARE Health Care
- SFBS Finance
- Exchange
- RARE Nasdaq
- SFBS Nasdaq
- Market Cap
- RARE 3.5B
- SFBS 4.1B
- IPO Year
- RARE 2014
- SFBS 2014
- Fundamental
- Price
- RARE $39.91
- SFBS $82.89
- Analyst Decision
- RARE Strong Buy
- SFBS Hold
- Analyst Count
- RARE 15
- SFBS 1
- Target Price
- RARE $90.53
- SFBS $84.00
- AVG Volume (30 Days)
- RARE 1.1M
- SFBS 296.8K
- Earning Date
- RARE 07-31-2025
- SFBS 07-21-2025
- Dividend Yield
- RARE N/A
- SFBS 1.62%
- EPS Growth
- RARE N/A
- SFBS 20.55
- EPS
- RARE N/A
- SFBS 4.40
- Revenue
- RARE $590,689,000.00
- SFBS $477,064,000.00
- Revenue This Year
- RARE $18.94
- SFBS $25.60
- Revenue Next Year
- RARE $28.93
- SFBS $13.11
- P/E Ratio
- RARE N/A
- SFBS $18.84
- Revenue Growth
- RARE 33.46
- SFBS 17.21
- 52 Week Low
- RARE $29.59
- SFBS $60.19
- 52 Week High
- RARE $60.37
- SFBS $101.37
- Technical
- Relative Strength Index (RSI)
- RARE 65.02
- SFBS 70.70
- Support Level
- RARE $35.51
- SFBS $76.36
- Resistance Level
- RARE $38.19
- SFBS $79.70
- Average True Range (ATR)
- RARE 1.58
- SFBS 1.93
- MACD
- RARE 0.20
- SFBS 0.89
- Stochastic Oscillator
- RARE 98.43
- SFBS 94.01
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About SFBS ServisFirst Bancshares Inc.
Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary, ServisFirst Bank. Through the bank, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.